ribosomal protein S2 pseudogene 5Genealiases: RPS2_20_1284 · bcm384
Q-omics provides the consensus-scored RPS2P5 profile across patient tissues and cancer cell-line models. RPS2P5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPS2P5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS2P5 RNA expression shows 15,635 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where RPS2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P5 survival associations across molecular data types. RPS2P5 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P5 RNA expression–survival associations across cancer types. High RPS2P5 expression shows unfavorable associations in KIRP, ACC, OV and LIHC, but favorable associations in UVM and GBM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPS2P5 RNA expression.
This table summarizes RPS2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P5 shows higher tumor expression in KIRC, KIRP, LIHC, COAD, LUSC and KICH. The KIRC box plot shows higher RPS2P5 RNA expression in tumor versus normal tissue (log2 FC = +1.488, t-test p < 0.001).
This table shows molecular features associated with RPS2P5 in patient tissues and cancer cell lines. In patient samples, RPS2P5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
